Anaveon to present first clinical data from the Phase I/II study of ANV419 at the AACR Annual Meeting 2022

 ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

Basel, March 9, 2022 – Anaveon, a clinical-stage immuno-oncology company, today announced that it will present first clinical data from the ongoing Phase I/II study of ANV419, a powerful and selective interleukin-2 (IL-2) agonist in patients with solid tumors, in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisana, April 8 to April 13, 2022. Abstracts will be available online starting 1:00 pm ET on Friday, April 8, 2022.

Details of the poster presentation are:

Abstract Title: “ANV419, an IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, induces selective effector cell proliferation in patients with progressed cancer” (download poster here)

Presentation Number: CT140
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 35

Poster Board Number:  7

Authors:  Elena Garralda, Guzman Alonso, Juanita Lopez, Heinz Läubli, Emiliano Calvo, Christoph Huber, Nicole Egli, Aswathy Nair, Kirsten Richter, Sangeetha Jetwa, Silvio Costanzo, Christoph Bucher
Date/Time: April 11, 2022 at 1:30 pm – 5:00 pm ET

Anaveon is undertaking a Phase I/II study to evaluate the safety, dosing and clinical activity of its lead program, ANV419, a powerful and selective interleukin-2 (IL-2) agonist in patients with solid tumors. The Company is pursuing multiple parallel Phase II programs in order to explore the full therapeutic potential of ANV419. In addition, Anaveon continues its work in developing follow-on compounds to expand on the success of ANV419 by delivering the IL-2 agonist to tumor fighting cells and thus expand the therapeutic potential into less immunogenic tumors. Alongside this, the Company is building on its cytokine engineering expertise with preclinical-stage programs harnessing the power of cytokines for therapeutic purposes.

ENDS

Enquiries

JW Communications
Julia Wilson
Tel: +44 (0)7818 430877
Email: julia.wilson@anaveon.com

About Anaveon:

Anaveon is a clinical-stage biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer patients. Our vision is to develop novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology. For further information please visit the Company’s website at: www.anaveon.com.

Latest News

29.05.2024
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study

— ANV600 combines a non-blocking αPD-1 antibody and an IL-2Rβ/γ selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential — Basel, 29 May 2024 – Anaveon, a clinical stage, immuno-oncology company, today announced that its Investigational New Drug…
Read more
14.12.2023
Anaveon announces publication of ANV419 Phase I clinical data in the Journal for ImmunoTherapy of Cancer ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

Anaveon announces publication of ANV419 Phase I clinical data in the Journal for ImmunoTherapy of Cancer

— ANV419 delivers high dose IL-2 to patients with a good safety and tolerability profile —
Basel, December 14, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced the publication of updated clinical data from the ongoing Phase I study of ANV419…
Read more
01.11.2023
Anaveon announces presentation of ANV600 preclinical data supporting combination therapy with therapeutic PD-1 inhibitors ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

Anaveon announces presentation of ANV600 preclinical data supporting combination therapy with therapeutic PD-1 inhibitors

— ANV600 is a potent, cis-signaling, IL-2Rβ/γ agonist which efficiently expands intratumoral stem-like CD8+ T cells —
Basel, November 1, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the 38th Annual Meeting…
Read more
Corporate Positioning & Design, Concept, Webdesign & Code:
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com
Our website uses cookies to provide you with the best online experience. By using our website, you accept the use of cookies in accordance with our Privacy Policy.
Accept